Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission

Tiziana Life Sciences ( (TLSA) ) has shared an update.

On March 4, 2025, Tiziana Life Sciences announced the submission of an Investigational New Drug (IND) application to the U.S. FDA for a phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). This marks a significant milestone in their efforts to develop a new treatment approach for ALS, supported by a grant from the ALS Association. The trial will evaluate the safety and early-stage efficacy of their novel intranasal foralumab, potentially improving outcomes for ALS patients. This development underscores Tiziana’s commitment to addressing urgent medical needs in neurodegenerative diseases.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, aimed at providing improved efficacy and safety compared to traditional intravenous delivery.

YTD Price Performance: 89.71%

Average Trading Volume: 830,927

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $142.8M

For an in-depth examination of TLSA stock, go to TipRanks’ Stock Analysis page.